Qualigen Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Kevin Richardson

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	2.2yrs

Recent management updates

Recent updates

CEO

Kevin Richardson (56 yo)

less than a year

Tenure

Mr. Kevin A. Richardson, II, is Interim CEO, Interim CFO & Director of Qualigen Therapeutics, Inc. from September 26, 2024. Mr. Richardson had been the Chairman at SANUWAVE Health, Inc. since October 2009...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Michael Poirier	Chief Operating Officer	no data	US$632.70k	0.078% $ 3.1k
Kevin Richardson	Interim CEO	less than a year	no data	no data
Campbell Becher	President & Independent Director	less than a year	no data	no data
Christopher Lotz	VP of Finance & Corporate Secretary	1.8yrs	US$3.02m	0.0046% $ 185.2

0.08yrs

Average Tenure

57.5yo

Average Age

Experienced Management: 7R9's management team is not considered experienced ( 0.1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Kevin Richardson	Interim CEO	less than a year	no data	no data
Campbell Becher	President & Independent Director	less than a year	no data	no data
Michael Gordon	Member of Scientific Advisory Board	2.2yrs	no data	no data
Anthony Tolcher	Member of Scientific Advisory Board	2.2yrs	no data	no data
Lillian Siu	Member of Scientific Advisory Board	2.2yrs	no data	no data
Robert Lim	Independent Director	less than a year	no data	no data
Wayne Klohs	Chair of Scientific Advisory Board	2.2yrs	no data	no data
Matthew Korenberg	Independent Director	4.4yrs	US$42.00k	0% $ 0
Patricia LoRusso	Member of Scientific Advisory Board	2.2yrs	no data	no data
Christopher Slapak	Member of Scientific Advisory Board	2.2yrs	no data	no data
Stephen Neidle	Member of Scientific Advisory Board	2.2yrs	no data	no data
Cody Price	Independent Director	less than a year	no data	no data

2.2yrs

Average Tenure

51yo

Average Age

Experienced Board: 7R9's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Qualigen Therapeutics Management

Management criteria checks 0/4

Key information

Recent management updates

Qualigen Therapeutics, Inc. Announces Chief Financial Officer Changes

Less than half of directors are independent

Qualigen Therapeutics, Inc., Annual General Meeting, Sep 17, 2024

Qualigen Therapeutics, Inc. Announces Board Changes

Qualigen Therapeutics, Inc. Announces Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and Director

Qualigen Therapeutics, Inc., Annual General Meeting, Jul 13, 2023

Recent updates

Qualigen Therapeutics, Inc. Announces Chief Financial Officer Changes

New major risk - Financial data availability

Qualigen Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3.458613 million.

Less than half of directors are independent

The Nasdaq Hearings Panel Grants Qualigen Therapeutics Until October 31, 2024 to Regain Compliance with the Bid Price Rule and the Equity Rule

Qualigen Therapeutics, Inc., Annual General Meeting, Sep 17, 2024

Qualigen Therapeutics, Inc. Announces Board Changes

Qualigen Therapeutics Receives Nasdaq Notice of a Delisting Determination Due to its Continued Non-Compliance with the Minimum Bid Price Requirement, Pursuant to Listing Rule 5550(b)(2)

Qualigen Therapeutics, Inc. announced delayed 10-Q filing

Qualigen Therapeutics, Inc. announced delayed annual 10-K filing

Qualigen Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Alpha Capital Anstalt

Qualigen Therapeutics Receives a Letter from the Nasdaq Stock Market

Third quarter 2023 earnings released: US$0.64 loss per share (vs US$0.97 loss in 3Q 2022)

Qualigen Therapeutics, Inc. Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$1.12 loss in 2Q 2022)

Qualigen Therapeutics Announces UD FDA IND Clearance to Initiate Phase 1 Clinical Trial of Qn-302 for Treatment of Advanced or Metastatic Solid Tumors

Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. (NasdaqCM:QLGN).

Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. (NasdaqCM:QLGN).

Qualigen Therapeutics, Inc. Announces Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and Director

Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Qualigen Therapeutics, Inc., Annual General Meeting, Jul 13, 2023

Qualigen Therapeutics, Inc. Announces the Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and A Director, Effective June 16, 2023

Full year 2022 earnings released: US$4.85 loss per share (vs US$6.10 loss in FY 2021)

Qualigen Therapeutics, Inc. Initiates Good Laboratory Practice Toxicology Studies on QN-302

Qualigen Therapeutics, Inc. Announces Executive Changes

Qualigen Therapeutics, Inc. announced that it expects to receive $3.3 million in funding

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Qualigen Therapeutics, Inc. Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

High number of new and inexperienced directors

Qualigen Therapeutics, Inc., Annual General Meeting, Oct 28, 2022

Nasdaq Grants Qualigen Therapeutics 180-Day Extension to February 27, 2023 to Regain Compliance with the Minimum Bid Price Requirement

High number of new and inexperienced directors

Qualigen Therapeutics, Inc. Announces Formation and First Meeting of QN-302 Scientific Advisory Board

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2021)

Qualigen Therapeutics, Inc. Reports Positive Qn-247 Readout in Triple Negative Breast Cancer in Vivo Model

Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials

Qualigen Therapeutics, Inc. (NasdaqCM:QLGN) completed the acquisition of a 53% stake in NanoSynex Ltd. from shareholder.

Qualigen Therapeutics, Inc. (NasdaqCM:QLGN) entered into definitive agreement to acquire an unknown majority stake in NanoSynex Ltd. from shareholder.

Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President

Full year 2021 earnings released: US$0.61 loss per share (vs US$1.50 loss in FY 2020)

Second quarter 2021 earnings released: US$0.18 loss per share (vs US$2.12 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.13 loss per share (vs US$0.16 loss in 1Q 2020)

Qualigen Therapeutics, Inc. Announces Management Changes

New 90-day low: €2.40

New 90-day high: €3.46

New 90-day low: €2.49

Qualigen Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Qualigen Therapeutics, Inc. Announces Issuance of U.S. Patent for Expanded Applications of ALAN Anticancer Platform Technology

Qualigen Therapeutics, Inc. Appoints Sidney Emery, Jr. as A Member of the Board

Qualigen Therapeutics, Inc. Completes Recertification of Existing AS1411 Drug Supply for Use in Upcoming Clinical Trials

New 90-day low: €2.73

New 90-day low: €3.25

Qualigen Therapeutics Enters into Commercialization Agreement for its FastPack® Diagnostic Products in China

Qualigen Therapeutics Expands Research Agreement with University of Louisville for ALAN Cancer Drug Candidate

Qualigen Therapeutics, Inc. and University of Louisville Announce Filing of U.S. Provisional Patent Application for the Use of AS1411 to Prevent Viral Infections

New 90-day low - €3.44

Earnings released

Qualigen Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $9.999996 million.

Qualigen Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8 million.

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age